Peter Kolchinsky, Research Alliance Corp II: Profile and Biography Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Prior to CVS Health, Prithviraj was a Senior Research Associate at the Gerson Lehrman Group. Prior to RA, Anthony completed the Biopharmaceutical Leadership Development Program at Reata Pharmaceuticals. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Abhishek gained experience using data analytics to track and visualize patient testing in his most recent role at Blueprint Medicines. RA Capital | Team Robert received his BS in mechanical engineering from the University of Houston. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Henry has a BA in Biology & Economics from Dartmouth College. James Schneider is the Deputy General Counsel at RA Capital Management. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. Meredith is a Senior Research Assistant at RA Capital Management. Mike earned his MBA from the Darden Graduate School of Business Administration. Mario has more than two decades of experience in vaccinology, virology and immunology in large pharma, government, academy, and biotech settings. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. Mark brings to RAVen more than twenty-five years of leadership experience in the life sciences industryspanning operations, corporate development, legal affairs, and intellectual property. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Prior to RA, Elena gained analyst and research experience through roles with Alira Health, Mandarin Capital Partners, LifeLineLab S.r.l. Pieter holds a BA from Trinity College and a JD from Yale Law School. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Prior to KPMG, Ryan worked at Morris and Morris, P.C. Priscilla has a B.S. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Most recently, Tom served as Director of Operations at TPRV Capital, LP. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Previously, Derek covered solid tumor oncology landscapes. Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. January 3, 2023 Feb 10th, Ed. Matt has a BA in Biology with minors in Mathematics and Physics from Ithaca College, a Master of Science in Bioinformatics from Northeastern University, and a PhD in Molecular Biology with a specialization in quantitative biology from Brandeis University. Previously, Gunes worked closely with the Investment Team, as a Senior Associate within RAs TechAtlas division. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Peter Kolchinsky, Ph.D. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Roivant, he . Anthonys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. He also provided additional system administration and training for the desktop engineering team. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Prior to joining RA, Kathryn was SVP of Strategy at Energetic Insurance where she addressed regulatory-driven commercial lender limitations to enable financing for renewable energy and efficiency via financial insurance products. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Senior Research Assistant, Venture Analytics. He conducted his postdoctoral research at Brigham and Womens Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis. Andrew is a Software Developer at RA Capital Management. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Alyssas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. 1 reply 0 retweets 13 likes Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Dan studied Network Communications & Information Services at Lincoln Technical. In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Kaleen Sullivan is a Research Operations Manager at RA Capital Management. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. Hearing the stories of how patients couldn't afford the . Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International. Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Sarah teaches a course at Harvard Law School on venture capital fund formation. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Garrett has over 20 years of experience in cell and gene therapy, including over 12 years in roles of increasing responsibility in biotech companies, including with Bluebird Bio, Audentes Therapeutics, and Ambys Medicines, and he was most recently the VP of Gene Therapy at Voyager Therapeutics. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. Rez has also held roles at Novartis, a virtual R&D company (BVD), and Xcellsyz Ltd, a UK-based start-up. Bethany is a Senior Finance Associate at RA Capital Management. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. In this role, Maryann supports start-up business infrastructure development for newcos as well as provides strategic HR guidance for founding team members. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (acquired by Sterling Pharma Solutions). Garrett Heffner is an EIR at RA Ventures, focusing on genetic medicines. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. Jaimie's primary responsibilities are to coordinate calendars, events, and company meetings for RA Venture Partners and EIRs. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. As political refugees, the family was placed in Milwaukee, then Pittsburgh. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. EMEA +44 20 7330 7500. Candice Galvez is an Executive Assistant at RA Capital Management. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Les primary responsibility is to coordinate various technology related initiatives across the company. The strange and special case of epinephrine | by Peter Kolchinsky | The from Yale and practiced as a cardiac anesthesiologist. April 28, 2023 9:39am. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. She received a B.Sc. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Le Ho is a Business Systems Analyst at RA Capital Management.
